Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUE-101 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Cue BioPharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CUE-101 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of human papillomavirus 16 (HPV16)-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). CUE-101 is a novel Immuno-STAT biologic designed to selectively activate and expand HPV16 E7-specific CD8+ T cells by delivering high concentrations of interleukin 2 (IL-2) directly to these tumor-specific T cells. Pembrolizumab, marketed as Keytruda, is a humanized monoclonal antibody that inhibits the programmed cell death protein 1 (PD‑1) immune checkpoint on lymphocytes, thereby enhancing anti-tumor immune responses. The combination aims to synergistically boost tumor-targeted immunity by both expanding antigen-specific cytotoxic T cells and blocking inhibitory PD‑1 signaling. Cue Biopharma develops CUE‑101; Merck & Co. develops pembrolizumab[1][3][4][5][6].
- Brand names
- Keytruda
- Other names
- CUE-101 + Keytruda
02
Targets
IL2RB (IL-2 receptor beta chain)Human papillomavirus type 16 E7 peptide-HLA-A*02:01 complexPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CUE-101 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUE-101 + pembrolizumab.